AstraZeneca launches Ambition Zero Carbon program for next-generation respiratory inhalers with Honeywell

Latest Pharma news

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.1

Today’s announcement coincides with the publication of the Company’s annual Sustainability Report and demonstrates progress on its flagship sustainability programme, Ambition Zero Carbon. The report also shows that the entirety of AstraZeneca’s imported electricity now comes from renewable sources and that the Company has achieved a 59% reduction in its Scope 1 and 2 greenhouse gas (GHG) emissions since 2015, including the integration of Alexion’s GHG footprint.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. Our collaboration with Honeywell demonstrates AstraZeneca’s commitment to advancing sustainable healthcare innovation, with the aim of improving outcomes for patients while reducing our environmental footprint.”

Darius Adamczyk, Chairman and Chief Executive Officer, Honeywell, said: “The work we are doing with AstraZeneca developing a respiratory inhaler, with a new near-zero Global Warming Potential propellant, is tremendously important for both the environment and patients with respiratory issues. Our goal is to reduce respiratory healthcare carbon emissions without restricting patient choice or risking improvement in health outcomes.”

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.1

Today’s announcement coincides with the publication of the Company’s annual Sustainability Report and demonstrates progress on its flagship sustainability programme, Ambition Zero Carbon. The report also shows that the entirety of AstraZeneca’s imported electricity now comes from renewable sources and that the Company has achieved a 59% reduction in its Scope 1 and 2 greenhouse gas (GHG) emissions since 2015, including the integration of Alexion’s GHG footprint.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon-negative across our entire value chain by 2030. Our collaboration with Honeywell demonstrates AstraZeneca’s commitment to advancing sustainable healthcare innovation, with the aim of improving outcomes for patients while reducing our environmental footprint.”

Darius Adamczyk, Chairman and Chief Executive Officer, Honeywell, said: “The work we are doing with AstraZeneca developing a respiratory inhaler, with a new near-zero Global Warming Potential propellant, is tremendously important for both the environment and patients with respiratory issues. Our goal is to reduce respiratory healthcare carbon emissions without restricting patient choice or risking improvement in health outcomes.”

Next-generation respiratory inhalers
Most patients with asthma and chronic obstructive pulmonary disease (COPD) need to be inhaled medicines2 and many make use of pressurised metered-dose inhalers (pMDIs)2 which contain small quantities of a type of GHG which acts as the propellant to deliver the medicine into the lungs.3

Recent results from the first-in-human Phase I trial of the near-zero GWP propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium, formoterol fumarate in healthy adults were positive, demonstrating similar safety, tolerability and systemic exposure of the active ingredients when compared to Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate). AstraZeneca expects Breztri to be the first medicine to transition to this new pMDI platform, subject to regulatory approval. In addition to offering next-generation pMDIs, AstraZeneca will continue offering dry powder inhaled medicines.

Respiratory diseases affect hundreds of millions of people around the world and there is a significant clinical need for pMDIs which are important device options for patients.4-9 Familiarity with device, limited lung function, and young or advanced age are all important considerations when choosing the type of inhaler that best suits the patient.5-9

Most patients with asthma and chronic obstructive pulmonary disease (COPD) need to be inhaled medicines2 and many make use of pressurised metered dose inhalers (pMDIs)2 which contain small quantities of a type of GHG which acts as the propellant to deliver the medicine into the lungs.3

Recent results from the first-in-human Phase I trial of the near-zero GWP propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium, formoterol fumarate in healthy adults were positive, demonstrating similar safety, tolerability and systemic exposure of the active ingredients when compared to Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate). AstraZeneca expects Breztri to be the first medicine to transition to this new pMDI platform, subject to regulatory approval. In addition to offering next-generation pMDIs, AstraZeneca will continue offering dry powder inhaled medicines.

Respiratory diseases affect hundreds of millions of people around the world and there is a significant clinical need for pMDIs which are important device options for patients.4-9 Familiarity with the device, limited lung function, and young or advanced age are all important considerations when choosing the type of inhaler that best suits the patient.5-9

Tags : #Astrazeneca #Honeywell #ZeroCarbonProgram #RespiratoryInhalers

About the Author


Snehangshu Dasgupta,

Managing Editor
[email protected]

Related Stories

Loading Please wait...

-Advertisements-


Trending Now

Is Liposuction surgery safe? Know the side effects of Liposuction Surgery May 21, 2022
The BD 'Advances in Clinical Flow Cytometry' Event provides clinicians with a rich knowledge-sharing platformMay 21, 2022
Omega 3 fatty acids – The essential fatMay 21, 2022
Vitamin B12 – Deficiency and sourcesMay 21, 2022
CDSCO has approved Boehringer Ingelheim's Jardiance for the treatment of heart failure.May 20, 2022
Hanuman raises over $.5 million to expand its emergency medical response services in Bihar, Jharkand and UP May 20, 2022
Sudden Infant Death Syndrome (SIDS) – Causes and preventive methodsMay 20, 2022
Healthcare Innovation Challenge: Data's Expanding Role in the Healthcare SectorMay 20, 2022
Homeopathy in Pregnancy - Homeopathy Treatment | MedicircleMay 20, 2022
MetroMedi launches the MetroMedi Relief platform for mental and sexual health wellbeing.May 20, 2022
Top Health Benefits for Butter milk May 20, 2022
Sumit Agarwal- Born with Cerabral Palsy to today being an acclaimed entrepreneur in the public relations industry in IndiaMay 20, 2022
Five eye hospitals in the Tri-city region have been acquired by Dr. Agarwal's Eye Hospital.May 19, 2022
World Family Doctor Day, 2022 – Family doctor makes care easily accessible May 19, 2022
Adani Enterprises will explore the healthcare industry.May 19, 2022
Tips for Weight Loss May 19, 2022
What should be the diet during menopause? May 19, 2022
5 Tips To Get Rid Of Cracked Heels In SummerMay 19, 2022
How is meditation beneficial in reducing low blood pressure?May 18, 2022
Why should we not eat mushrooms because of kidney disease? May 18, 2022